All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

PFEPfizer
0Calm
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Signing up patientsPhase 3680 patientsMain results: Mar 10, 2028
REGNRegeneron Pharmaceuticals
5Calm
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Signing up patientsPhase 3975 patientsMain results: Jul 31, 2028
MRKMerck Sharp & Dohme LLC
2Calm
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
Signing up patientsPhase 2480 patientsMain results: Sep 26, 2028
PFEPfizer
0Calm
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Running, no new patientsPhase 3841 patientsMain results: Mar 1, 2025
BMYBristol-Myers Squibb
3Calm
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Signing up patientsPhase 2/3690 patientsMain results: Nov 8, 2030
RLAYRelay Therapeutics, Inc.
9Calm
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Signing up patientsPhase 3540 patientsMain results: Apr 30, 2028
ONCYOncolytics Biotech
0Calm
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Signing up patientsPhase 260 patientsMain results: Aug 30, 2027
MRKMerck Sharp & Dohme LLC
2Calm
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Signing up patientsPhase 31,310 patientsMain results: Nov 30, 2028
ALXOALX Oncology Inc.
14Calm
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
FinishedPhase 2/3127 patientsMain results: May 24, 2024
MRKMerck Sharp & Dohme LLC
2Calm
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
FinishedPhase 1/235 patientsMain results: Sep 30, 2026
REGNRegeneron Pharmaceuticals
5Calm
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Signing up patientsPhase 1/2150 patientsMain results: Sep 30, 2033
REGNRegeneron Pharmaceuticals
5Calm
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Signing up patientsPhase 31,600 patientsMain results: Jul 18, 2031
MRKMerck Sharp & Dohme LLC
2Calm
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
Not started yetPhase 2/3470 patientsMain results: Mar 13, 2037
BMYBristol-Myers Squibb
3Calm
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Signing up patientsPhase 3850 patientsMain results: Sep 18, 2030
AGENAgenus Inc.
0Calm
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Running, no new patientsPhase 2234 patientsMain results: Sep 2027
SMMTSummit Therapeutics
0Calm
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Signing up patientsPhase 3900 patientsMain results: May 31, 2028
BMYJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
3Calm
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Signing up patientsPhase 265 patientsMain results: Jan 9, 2028
CNSYCerenome
0Calm
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Signing up patientsPhase 1/224 patientsMain results: Jul 31, 2027
MRKMerck Sharp & Dohme LLC
2Calm
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Signing up patientsPhase 2/3380 patientsMain results: Jun 25, 2032
GLUEMonte Rosa Therapeutics, Inc
3Calm
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Signing up patientsPhase 225 patientsMain results: Oct 2027
JNJJanssen Research & Development, LLC
2Calm
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Signing up patientsPhase 3199 patientsMain results: Nov 17, 2023
MRKMerck Sharp & Dohme LLC
2Calm
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Signing up patientsPhase 31,530 patientsMain results: Dec 16, 2030
PFEPfizer
0Calm
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Running, no new patientsPhase 3599 patientsMain results: Feb 18, 2026
REGNRegeneron Pharmaceuticals
5Calm
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Signing up patientsPhase 31,120 patientsMain results: Jan 23, 2030
CADLCandel Therapeutics, Inc.
10Calm
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Running, no new patientsPhase 290 patientsMain results: Dec 31, 2024